Previous 10 | Next 10 |
2024-05-29 12:11:20 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Addressing Supply Challenges Should Accelerate Growth SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Novo Nordisk: The Market Is Right, Don't Fight Against It SA Asks: Who...
2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...
2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 10:18:39 ET More on Novo Nordisk, Catalent Catalent - Novo Holdings Merger: Attractive Spread Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Consid...
2024-05-29 09:25:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-28 21:19:27 ET Summary Chase Coleman's Tiger Global Management 13F portfolio value increased from $14.1B to $18.3B this quarter. The largest five positions in the portfolio are Meta Platforms, Microsoft, Alphabet, Apollo Global, and Amazon.com. New stakes include Liber...
2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...
2024-05-28 14:36:30 ET Summary Calamos Global Dynamic Income Fund offers high-income and geographic diversification, without sacrificing equity exposure. The fund's distribution yield of 9.00% is lower than its peers, but it has delivered strong recent performance and total return...
2024-05-28 12:02:07 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Who will launch the next bi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...